Abata Therapeutics

Senior Director, Clinical Contracts Attorney

Remote

Auto‑apply with AI Apply

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

BiotechnologyIndustries

Requirements

The Senior Director, Clinical Contracts Attorney should possess a Juris Doctor degree and be admitted to practice law in at least one U.S. state, with experience in the biotechnology industry and a strong understanding of clinical trial agreements, informed consent forms, and contract research organization agreements. Ideal candidates will have expertise in all legal aspects of clinical trial operations, including healthcare fraud and abuse, pharmacovigilance, product liability, antitrust, and privacy, and be able to independently manage workflows and projects.

Responsibilities

This role involves providing legal contract support for US and global clinical development, leading negotiations and drafting agreements for all phases of clinical development, serving as a legal representative in clinical trial team meetings, providing guidance to third-party vendors, managing legal professionals assisting with contract review, contributing to maintaining a legal and compliance team, fostering collaborative relationships with colleagues, identifying ways to improve processes, and cultivating a company culture that reflects a commitment to ethics and patients.

Skills

Clinical Contracts

Biotech

Legal

Negotiation

Clinical Trials

Contract Negotiation

Abata Therapeutics

Develops therapies for autoimmune diseases

About Abata Therapeutics

Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Unlike many competitors, Abata targets a specific niche within the autoimmune disease market and collaborates with partners like ElevateBio for process development and manufacturing. The company's goal is to transform treatment options for autoimmune diseases through advanced research and development.

Key Metrics

Cambridge, MassachusettsHeadquarters

2021Year Founded

$184.8MTotal Funding

EARLY_VCCompany Stage

BiotechnologyIndustries

11-50Employees

Risks

Intensifying competition from companies like Sangamo Therapeutics may impact Abata's market share.

Stringent FDA scrutiny on manufacturing could delay Abata's clinical trials.

Rising clinical trial costs pose financial risks to Abata's pipeline progression.

Differentiation

Abata focuses on Treg cell therapies for autoimmune diseases like MS and diabetes.

Their lead product, ABA 201, targets type 1 diabetes with remaining beta cell function.

Abata's strategic partnership with ElevateBio enhances their manufacturing capabilities.

Upsides

Recent investment from Bristol Myers Squibb boosts Abata's Treg therapy pipeline development.

FDA's accelerated approval pathways may expedite Abata's clinical trials.

Growing autoimmune disease prevalence increases demand for Abata's innovative treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free